[{"id":"b3d6c3c2-daaa-494a-aacb-7469cd76f192","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929028","created_at":"2021-06-18T23:52:29.721Z","updated_at":"2025-02-25T16:32:30.069Z","phase":"Phase 2","brief_title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","source_id_and_acronym":"NCT04929028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1 • IFNG • CD4","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 09/15/2029","primary_completion_date":" 09/15/2029","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2025-02-07"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"af1036ff-3e62-4e96-a286-d3b0fe2e8708","acronym":"NIVEAU","url":"https://clinicaltrials.gov/study/NCT03366272","created_at":"2021-01-17T17:15:43.143Z","updated_at":"2025-02-25T14:37:49.011Z","phase":"Phase 2/3","brief_title":"Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","source_id_and_acronym":"NCT03366272 - NIVEAU","lead_sponsor":"Universität des Saarlandes","biomarkers":" CD20","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 348","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2025-01-28"},{"id":"949b2ac3-8269-489d-a405-99b472b2028a","acronym":"CA209-6D9","url":"https://clinicaltrials.gov/study/NCT05704933","created_at":"2023-01-30T15:59:33.242Z","updated_at":"2025-02-25T14:17:35.071Z","phase":"Phase 1","brief_title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","source_id_and_acronym":"NCT05704933 - CA209-6D9","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • PD-1 • IFNG • CD4 • IL2 • IL10","pipe":" | ","alterations":" PD-1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-09"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"131edcdb-27c4-4090-85ed-cdfe17502f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743766","created_at":"2021-01-18T18:20:12.816Z","updated_at":"2025-02-25T14:27:49.581Z","phase":"Phase 2","brief_title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","source_id_and_acronym":"NCT03743766","lead_sponsor":"John Kirkwood","biomarkers":" PD-1 • LAG3","pipe":" | ","alterations":" PD-1 expression • LAG3 expression","tags":["PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-09-25"},{"id":"a89a199c-8105-44bd-a321-b07e9e8b9417","acronym":"NCI-2018-02529","url":"https://clinicaltrials.gov/study/NCT03316274","created_at":"2021-01-18T16:22:38.781Z","updated_at":"2025-02-25T14:37:35.336Z","phase":"Phase 1","brief_title":"Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma","source_id_and_acronym":"NCT03316274 - NCI-2018-02529","lead_sponsor":"University of California, San Francisco","biomarkers":" PD-L1 • IFNG • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2024-06-25"},{"id":"1c8b1550-7e80-4765-97fb-ec60f41f7c80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04931017","created_at":"2021-06-18T22:52:31.039Z","updated_at":"2024-07-02T16:35:09.374Z","phase":"Phase 2","brief_title":"Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer","source_id_and_acronym":"NCT04931017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • IL6 • TNFA","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/09/2022","start_date":" 09/09/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-04-16"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"34bd7357-c6cb-4bf9-9075-eee009558802","acronym":"PREDICT","url":"https://clinicaltrials.gov/study/NCT06304597","created_at":"2024-03-13T08:35:57.626Z","updated_at":"2024-07-02T16:35:15.305Z","phase":"Phase 1","brief_title":"Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy","source_id_and_acronym":"NCT06304597 - PREDICT","lead_sponsor":"University Medical Center Groningen","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imfinzi (durvalumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-11"},{"id":"6b69a04e-98c0-4bfd-b825-c53f82dd8ac3","acronym":"NCI-2016-01233","url":"https://clinicaltrials.gov/study/NCT02935361","created_at":"2024-02-14T01:26:00.848Z","updated_at":"2024-07-02T16:35:19.676Z","phase":"Phase 1/2","brief_title":"Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed","source_id_and_acronym":"NCT02935361 - NCI-2016-01233","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/02/2016","start_date":" 11/02/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-02-13"},{"id":"5e7cf487-6afc-4a5b-a461-e3b7382a644d","acronym":"ARIES","url":"https://clinicaltrials.gov/study/NCT03891238","created_at":"2021-01-18T19:09:52.070Z","updated_at":"2024-07-02T16:35:21.322Z","phase":"Phase 2","brief_title":"Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study","source_id_and_acronym":"NCT03891238 - ARIES","lead_sponsor":"Consorzio Oncotech","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Bavencio (avelumab)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 02/06/2019","start_date":" 02/06/2019","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 09/15/2021","study_completion_date":" 09/15/2021","last_update_posted":"2024-02-01"},{"id":"82013286-70fc-49b1-bd27-fd2d41b85ce4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493060","created_at":"2021-01-18T21:35:01.218Z","updated_at":"2024-07-02T16:35:22.947Z","phase":"Phase 2","brief_title":"Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04493060","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • BRCA1 • BRCA2 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/07/2023","primary_completion_date":" 12/07/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-01-19"},{"id":"69ad849e-4635-4dad-91b2-0aa351bab75b","acronym":"AVENuE","url":"https://clinicaltrials.gov/study/NCT03617666","created_at":"2023-12-12T17:16:58.708Z","updated_at":"2024-07-02T16:35:26.455Z","phase":"Phase 2","brief_title":"Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study","source_id_and_acronym":"NCT03617666 - AVENuE","lead_sponsor":"University College, London","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 07/04/2022","primary_completion_date":" 07/04/2022","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2023-12-12"},{"id":"bdf79ea5-8210-46ea-be22-221f8b052253","acronym":"TILS001","url":"https://clinicaltrials.gov/study/NCT05451784","created_at":"2022-07-11T11:54:53.836Z","updated_at":"2024-07-02T16:35:28.136Z","phase":"Phase 1/2","brief_title":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","source_id_and_acronym":"NCT05451784 - TILS001","lead_sponsor":"Fundacio Clinic Barcelona","biomarkers":" HER-2 • PD-1","pipe":" | ","alterations":" HER-2 negative • PD-1 expression • PGR expression","tags":["HER-2 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-1 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NUMARZU-001"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2023-11-24"},{"id":"f7a455b0-deea-482b-94fb-d6d103d8b118","acronym":"ATHENA","url":"https://clinicaltrials.gov/study/NCT03818061","created_at":"2021-01-18T18:51:49.787Z","updated_at":"2024-07-02T16:35:35.321Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT03818061 - ATHENA","lead_sponsor":"Centre Leon Berard","biomarkers":" PD-L1 • PD-1 • IL2","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-09-28"},{"id":"0044ea75-ae77-4594-812e-5bf0e18635e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02499835","created_at":"2021-01-18T12:03:40.058Z","updated_at":"2024-07-02T16:35:41.378Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer","source_id_and_acronym":"NCT02499835","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MVI-816"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 08/09/2021","primary_completion_date":" 08/09/2021","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2023-08-01"},{"id":"00d2b65c-9b1a-4495-8d01-f44dad6e0734","acronym":"ATEZOGIST","url":"https://clinicaltrials.gov/study/NCT05152472","created_at":"2021-12-09T18:00:33.920Z","updated_at":"2024-07-02T16:35:41.546Z","phase":"Phase 2","brief_title":"A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments","source_id_and_acronym":"NCT05152472 - ATEZOGIST","lead_sponsor":"Centre Leon Berard","biomarkers":" PD-L1 • PD-1 • IL2","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • PD-1 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-08-01"},{"id":"b164720f-5172-4d76-9e1c-1b0c40d01f11","acronym":"","url":"https://clinicaltrials.gov/study/NCT05562297","created_at":"2022-09-30T19:56:06.889Z","updated_at":"2024-07-02T16:35:44.585Z","phase":"Phase 2","brief_title":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","source_id_and_acronym":"NCT05562297","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-1 • MUC16","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Tyvyt (sintilimab) • albumin-bound paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-06-27"},{"id":"58ad1cf0-b0ae-467d-991a-a5d900291a36","acronym":"IMMUVIX","url":"https://clinicaltrials.gov/study/NCT03255252","created_at":"2021-01-18T16:04:49.386Z","updated_at":"2024-07-02T16:35:46.214Z","phase":"Phase 2","brief_title":"Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy","source_id_and_acronym":"NCT03255252 - IMMUVIX","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" CD8 • PD-1 • HAVCR2 • CD4 • ENTPD1","pipe":" | ","alterations":" PD-1 expression • CD8 expression • ENTPD1 expression","tags":["CD8 • PD-1 • HAVCR2 • CD4 • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • CD8 expression • ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 06/16/2022","primary_completion_date":" 06/16/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-06-07"},{"id":"48e9888e-1610-4808-9875-839623d633eb","acronym":"CP-COPD","url":"https://clinicaltrials.gov/study/NCT04654104","created_at":"2021-01-19T20:41:13.728Z","updated_at":"2024-07-02T16:36:00.909Z","phase":"","brief_title":"Immune Checkpoints in COPD","source_id_and_acronym":"NCT04654104 - CP-COPD","lead_sponsor":"University of Catanzaro","biomarkers":" PD-L1 • PD-1 • CTLA4 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression","tags":["PD-L1 • PD-1 • CTLA4 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • HAVCR2 expression • CTLA4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 12/10/2023","study_completion_date":" 12/10/2023","last_update_posted":"2022-11-07"},{"id":"2bb7d6c9-0473-46c7-9460-ae9487c6e000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04679480","created_at":"2021-01-19T20:46:22.519Z","updated_at":"2024-07-02T16:36:00.949Z","phase":"Phase 2","brief_title":"Anti-PD1-antibody and Pulsed HHI for Advanced BCC","source_id_and_acronym":"NCT04679480","lead_sponsor":"Reinhard Dummer","biomarkers":" CD8 • PD-1 • CD4 • CD200 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression","tags":["CD8 • PD-1 • CD4 • CD200 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-04"},{"id":"04cd97a4-ff0e-4f08-be80-15f3b135338e","acronym":"TRUCE-04","url":"https://clinicaltrials.gov/study/NCT05495724","created_at":"2022-08-10T12:55:33.512Z","updated_at":"2024-07-02T16:36:05.714Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable","source_id_and_acronym":"NCT05495724 - TRUCE-04","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" HER-2 • PD-L1 • TMB • PD-1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • PD-1 expression","tags":["HER-2 • PD-L1 • TMB • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-08-10"},{"id":"a9a4b065-a72c-4e31-861d-bbef6a0e8d93","acronym":"PEOPLE","url":"https://clinicaltrials.gov/study/NCT03447678","created_at":"2021-01-18T16:59:58.507Z","updated_at":"2024-07-02T16:36:29.303Z","phase":"Phase 2","brief_title":"Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.","source_id_and_acronym":"NCT03447678 - PEOPLE","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression","tags":["EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-06-09"}]